Engineered immune cells get a navigation system to hunt down lymphoma
NCT ID NCT03602157
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-phase study tests a new treatment for people with certain types of lymphoma that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells, plus an added navigation protein (CCR4) to help them find tumors. The main goal is to find a safe dose and see if the cells can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.